GlassScriptPhysician profile
Robert A Binard
NPI 1497429260
$1,826.52
in general payments reported to CMS, 2019-2025
22 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.08 · 2023: $453 · 2024: $719 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $303.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $274.65 | 2023-2025 | |
| Abbvie INC. | $241.85 | 2023-2025 | |
| Mylan Specialty L.P. | $121.86 | 2022-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $109.56 | 2024-2025 | Airsupra, Farxiga |
| Amgen INC. | $94.40 | 2023-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $92.61 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $91.99 | 2022-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $73.46 | 2022-2025 | |
| Viatris Specialty LLC | $58.49 | 2025 | Yupelri |
| Exact Sciences Corporation | $46.21 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.52 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.36 | 2024-2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $38.76 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $37.21 | 2023-2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.34 | 2024-2025 | Sunosi |
| Verona Pharma, INC. | $23.06 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $20.45 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $19.33 | 2025 | Nexletol |
| Eisai INC. | $19.27 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2025 | Xifaxan |
| Abbott Laboratories | $18.90 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Binard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.